Doctor Allan, Zimmerman Jerry, Agus Michael, Rajasekaran Surender, Bubeck Wardenburg Juliane, Fortenberry James, Zajicek Anne, Mairson Emma, Typpo Katri
1Departments of Pediatrics (Critical Care Medicine) and Biochemistry, Washington University in St. Louis, St. Louis, MO. 2Department of Pediatrics (Critical Care Medicine), University of Washington, Seattle, WA. 3Department of Pediatrics (Critical Care Medicine), Harvard University, Boston, MA. 4Department of Pediatrics (Critical Care Medicine), Michigan State University, Grand Rapids, MI. 5Departments of Pediatrics (Critical Care Medicine) and Microbiology, University of Chicago, Chicago, IL. 6Department of Pediatrics (Critical Care Medicine), Emory University, Atlanta, GA. 7Obstetric and Pediatric Pharmacology and Therapeutics Branch, NICHD, Bethesda, MD. 8Department of Pediatrics (Critical Care Medicine), University of Arizona, Phoenix, AZ.
Pediatr Crit Care Med. 2017 Mar;18(3_suppl Suppl 1):S67-S82. doi: 10.1097/PCC.0000000000001053.
To describe the state of the science, identify knowledge gaps, and offer potential future research questions regarding promising therapies for children with multiple organ dysfunction syndrome presented during the Eunice Kennedy Shriver National Institute of Child Health and Human Development Workshop on Pediatric Multiple Organ Dysfunction Syndrome (March 26-27, 2015).
Literature review, research data, and expert opinion.
Not applicable.
Moderated by an expert from the field, issues relevant to the association of multiple organ dysfunction syndrome with a variety of conditions were presented, discussed, and debated with a focus on identifying knowledge gaps and research priorities.
Summary of presentations and discussion supported and supplemented by relevant literature.
Among critically ill children, multiple organ dysfunction syndrome is relatively common and associated with significant morbidity and mortality. For outcomes to improve, effective therapies aimed at preventing and treating this condition must be discovered and rigorously evaluated. In this article, a number of potential opportunities to enhance current care are highlighted including the need for a better understanding of the pharmacokinetics and pharmacodynamics of medications, the effect of early and optimized nutrition, and the impact of effective glucose control in the setting of multiple organ dysfunction syndrome. Additionally, a handful of the promising therapies either currently being implemented or developed are described. These include extracorporeal therapies, anticytokine therapies, antitoxin treatments, antioxidant approaches, and multiple forms of exogenous steroids. For the field to advance, promising therapies and other therapies must be assessed in rigorous manner and implemented accordingly.
描述科学现状,识别知识空白,并针对尤妮斯·肯尼迪·施莱佛国家儿童健康与人类发展研究所小儿多器官功能障碍综合征研讨会(2015年3月26 - 27日)上提出的针对小儿多器官功能障碍综合征的有前景的治疗方法,提出未来潜在的研究问题。
文献综述、研究数据和专家意见。
不适用。
由该领域的一位专家主持,介绍、讨论并辩论了与多器官功能障碍综合征与多种病症关联相关的问题,重点是识别知识空白和研究重点。
由相关文献支持和补充的报告及讨论总结。
在危重症儿童中,多器官功能障碍综合征相对常见,且与显著的发病率和死亡率相关。为改善预后,必须发现并严格评估旨在预防和治疗该病症的有效疗法。在本文中,强调了一些增强当前护理的潜在机会,包括需要更好地理解药物的药代动力学和药效学、早期和优化营养的效果以及在多器官功能障碍综合征背景下有效控制血糖的影响。此外,还描述了一些目前正在实施或研发的有前景的疗法。这些包括体外疗法、抗细胞因子疗法、抗毒素治疗、抗氧化方法以及多种形式的外源性类固醇。为推动该领域发展,必须严格评估有前景的疗法和其他疗法并相应实施。